Drug intelligence / Profile preview

esketamine + duloxetine

Development stage: Unknown
Lead developer: Janssen Pharmaceutical
Modality: Small Molecules
Administration: Intranasal, Oral

Overview

A combination therapy consisting of esketamine nasal spray and oral duloxetine. Esketamine is an NMDA receptor antagonist that provides rapid relief from depression symptoms, while duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that offers longer-term management of depression. This combination is primarily used for treatment-resistant depression, with esketamine administered in a medically-supervised setting due to risks of sedation and dissociation.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on esketamine + duloxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on esketamine + duloxetine.

Explore the full profile